|
HEPARIN DERIVATIVES AS ANGIOGENESIS INHIBITORS
|
M Presta, D. Leali, H. Stabile, R. Ronca, M. Camozzi, L. Coco, E. Moroni, §S. Liekens, and M. Rusnati
Unit of General Pathology and Immunology, Department of Biomedical Science and Biotechnology, School of Medicine, University of Brescia, 25123 Brescia, Italy. §Present address: Department Cell Biology, New York University Medical Center, New York, NY, USA.
| 3D
structure of FGF2-PAMPS complex
If the plug-in named ChemScape Chime
is properly installed on your computer, you should see a FGF2-PAMPS complex.
The molecule can be moved by clicking it with the left button of
your mouse and its characteristics, including automatic rotation, can
be modified by clicking it with the right button.
|
ABSTRACT Angiogenesis is the process of generating new capillary
blood vessels. Uncontrolled endothelial cell proliferation is observed
in tumor neovascularization and in angioproliferative diseases. Tumors
cannot growth as a mass above few mm3 unless a new blood supply is induced.
It derives that the control of the neovascularization process may affect
tumor growth and may represent a novel approach to tumor therapy. Heparan sulfate proteoglycans are involved in the modulation of the neovascularization that takes place in different physiological and pathological conditions. This modulation occurs through the interaction with angiogenic growth factors or with negative regulators of angiogenesis. Thus, the study of the biochemical bases of this interaction may help to design glycosaminoglycan analogs endowed with angiostatic properties. The purpose of this review is to provide an overview
of the structure/function of heparan sulfate proteoglycans in endothelial
cells and to summarize the angiostatic properties of synthetic heparin-like
compounds, chemically modified heparins, and biotechnological heparins.
Curr. Pharmaceutical Design (2003) 9:553-566. |
AIRC: Special Project Angiogenesis